These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23259552)

  • 1. Impact of pre-diabetes and diabetes on cardiovascular outcomes.
    Anselmino M; Sillano D
    Curr Vasc Pharmacol; 2012 Nov; 10(6):680-3. PubMed ID: 23259552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is glycemic control a quinidine-like intervention?
    Bloomgarden ZT
    J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
    Wareham NJ; Pfister R
    Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comment from the diabetology viewpoint].
    Stahl M
    Praxis (Bern 1994); 2008 Aug; 97(17):943-4. PubMed ID: 18777777
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
    Hopper I; Billah B; Skiba M; Krum H
    Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Questions for practicing internists].
    Zinnenlauf S
    Praxis (Bern 1994); 2008 Aug; 97(17):945-6. PubMed ID: 18777778
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
    Shehadeh N; Raz I; Nakhleh A
    Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
    [No Abstract]   [Full Text] [Related]  

  • 10. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
    Borghi C; Ventura F
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial.
    Baye E; Menon K; de Courten MP; Earnest A; Cameron J; de Courten B
    BMJ Open; 2017 Sep; 7(9):e017691. PubMed ID: 28864708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk stratification and management in pre-diabetes.
    Færch K; Vistisen D; Johansen NB; Jørgensen ME
    Curr Diab Rep; 2014 Jun; 14(6):493. PubMed ID: 24743942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glycemic control and cardiovascular benefit: what do we know today?].
    Egidi G; Popert U
    Dtsch Med Wochenschr; 2011 May; 136(19):1027; author reply 1027-8. PubMed ID: 21544796
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes. Insights from the extended follow-up of the ACCORD trial.
    Zoungas S; Woodward M
    Nat Rev Cardiol; 2011 Jun; 8(6):308-10. PubMed ID: 21502962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study.
    Perreault L; Temprosa M; Mather KJ; Horton E; Kitabchi A; Larkin M; Montez MG; Thayer D; Orchard TJ; Hamman RF; Goldberg RB;
    Diabetes Care; 2014 Sep; 37(9):2622-31. PubMed ID: 24969574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of prediabetes.
    Priya G
    J Pak Med Assoc; 2018 Apr; 68(4):669-671. PubMed ID: 29808066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysglycemia/prediabetes and cardiovascular risk factors.
    Hanna-Moussa A; Gardner MJ; Kurukulasuriya LR; Sowers JR
    Rev Cardiovasc Med; 2009; 10(4):202-8. PubMed ID: 20065930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
    Cavalot F
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.